«The risk of cognitive impairment should be considered when deciding whether or not to
receive androgen deprivation therapy for prostate cancer,» said Brian Gonzalez, Ph.D., a postdoctoral fellow in the Health Outcomes and Behavior Program at Moffitt.
Twenty - two patients with elevated prostate - specific antigen and biopsy - proven prostate carcinoma who underwent MRI of the prostate at 1.5 T with endorectal coil were divided into two groups: those who were treated with
androgen deprivation, radiation therapy, or both, and a Gleason - matched control group who had not
received such therapy.